Pharmaceuticals

Eli Lilly signs agreement to acquire Morphic for $3.2 billion

bexib
By bexib 0 Min Read

The acquisition of Morphic is intended to strengthen treatment options for inflammatory bowel disease and expand Lilly’s gastroenterology portfolio.

You Might Also Like

Can Data and AI Enable Whole Person Health?

Urogen Pharma Submits New Drug Application to FDA for UGN-102, a Potential Treatment for Low-Grade, Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

FDA Issues Draft Guidelines on Diversity of Clinical Trial Populations

Patients and Data Disrupt Life Sciences

Unveils AI-powered virtual assistant for self-funded health plans’ digital health networks

Share This Article
Previous Article The return of pointless competition
Next Article The impact on trucking companies and the importance of liability insurance
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Strong spirit in tough times: New Zealand industry adapts
Hospitality & Tourism
Maker Spotlight: DIY Games by Hamza Mahmoud
Manufacturing
Top 5 Stories of 2024, Chosen by Readers
Banking
New Web Design Tools, December 2024
Retail & E-commerce